Seventy-one patients with oropharyngeal candidosis received treatment with fluconazole given as a single 50 mg capsule once daily. Of these patients 61 were HIV-antibody positive. Candidosis had been present in nearly all patients for a least one month prior to fluconazole treatment. The duration of daily therapy was 5-20 days and in many cases this was followed by a period of maintenance treatment using 50 mg fluconazole every 48 h. In all 42 symptomatic patients, clinical resolution of the infection occurred within 7 days. Significantly, this included the disappearance of dysphagia in four patients with proven candidal oesophagitis. A marked reduction, or eradication of oral yeasts occurred concomitantly in virtually all patients. Fluconazole was well tolerated by all patients and there were no significant changes in haematological or hepatic parameters that could be attributed to the drug. The results suggest that fluconazole is an appropriate treatment for oropharyngeal candidosis and comparative studies with other agents should now be conducted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02681218880000081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unusual Presentation of Extrapulmonary Tuberculosis as Laryngeal Mass in an Atypical Patient.
Case Rep Med
December 2024
Department of Otolaryngology, Head and Neck Surgery, Saint Louis University School of Medicine, St Louis, Missouri, USA.
Spread of Mycobacterium tuberculosis (MTB) to the larynx is exceedingly rare and can be obscured by more common conditions such as laryngeal cancer or oropharyngeal candidiasis, complicating an accurate diagnosis. Risk factors for chronic laryngeal disease, such as smoking and toxin exposure, place TB infection comparatively lower for consideration on a physician's differential. However, identifying these lesions is crucial from a medical and public health perspective to prevent community spread.
View Article and Find Full Text PDFClinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis.
Aliment Pharmacol Ther
February 2025
Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).
Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.
Extracellular hydrolytic enzyme activities and biofilm formation in Candida species isolated from people living with human immunodeficiency virus with oropharyngeal candidiasis at HIV/AIDS clinics in Uganda.
Microb Pathog
February 2025
Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, P.O. Box 7072, Makerere University, Kampala, Uganda. Electronic address:
Article Synopsis
- Commensal oral Candida species can turn pathogenic in people with weakened immune systems, leading to oropharyngeal candidiasis (OPC) due to various factors.
- The study assessed several enzymatic activities (phospholipase, proteinase, hemolysin, esterase, and coagulase) and biofilm formation in 35 Candida isolates from people living with HIV experiencing OPC.
- Results revealed that most isolates exhibited strong phospholipase and proteinase activities, with significant biofilm formation, while other enzymatic activities were less prevalent.
Prevalence, virulence factors and antifungal susceptibility of oral isolates of Candida albicans from patients with cystic fibrosis in Mexico.
Rev Iberoam Micol
December 2024
Universidad Autónoma de Nuevo León, Departamento de Microbiología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico. Electronic address:
Background: Candida species are frequently isolated from the oral cavity of patients with cystic fibrosis. However, the information on the role of Candida in cystic fibrosis is scarce.
Aims: This study aimed to evaluate the prevalence, virulence profile and antifungal susceptibility of oral isolates of Candida albicans recovered from patients with cystic fibrosis.
Distribution of Candida species isolated from people living with human immunodeficiency virus with oropharyngeal and oral candidiasis in Africa in the era of universal test and treat policy: a systematic review and meta-analysis.
Trop Med Health
November 2024
Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, P.O. Box 7072, Kampala, Uganda.
Article Synopsis
- The study examines the prevalence of Candida species causing oropharyngeal and oral candidiasis among individuals with HIV in Africa, in light of improved treatments like antiretroviral therapy and the universal test and treat (UTT) policy.
- It analyzed data from 14 studies involving over 4,200 participants, finding that a significant majority of the Candida species isolated were C. albicans, while non-albicans species like C. glabrata and C. tropicalis were also present.
- The research indicates a decrease in the prevalence of oropharyngeal candidiasis since the introduction of UTT, with a pooled prevalence of 48%, suggesting effective interventions, although certain challenges remain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!